N11 — Infection Control: Hepatitis B and C, Vaccination, Isolation FRONT
Front · at the chair
When: admission or transfer, every serology result, and every vaccine decision.
Do this
- New patient or transfer: hepatitis B triple panel — HBsAg, anti-HBs, total anti-HBc [4] — and an HCV screen [3], with results known before or at the first treatment per your unit protocol.
- Ongoing testing by status [1,3]:
- Hepatitis B susceptible (not immune): HBsAg monthly.
- Immune (anti-HBs 10 mIU/mL or higher): anti-HBs yearly; booster if it falls below 10.
- Hepatitis C: antibody or RNA test every 6 months; ALT monthly.
- Vaccinate every susceptible patient with a hemodialysis regimen [2]:
- Recombivax HB dialysis formulation 40 mcg — 3 doses (0, 1, 6 months), or
- Engerix-B 40 mcg (two 20-mcg doses) — 4 doses (0, 1, 2, 6 months).
- Check anti-HBs 1–2 months after the last dose. Below 10 mIU/mL: repeat the full series once [1].
- Other vaccines per the current ACIP adult schedule: yearly influenza, pneumococcal (PCV20 or PCV21), COVID-19, RSV at 50 or older (dialysis counts as a risk condition), Tdap, recombinant zoster at 50 or older ( screening white paper §8.4, verified against CDC 2026 schedules).
- HBsAg-positive patient: separate room; dedicated machine, equipment, supplies, and medications; staff who are not caring for susceptible patients at the same time; no dialyzer reuse [1].
- Every station, every patient: clean the chair, surfaces, and machine exterior; replace transducer protectors; clean blood spills right away with a disinfectant your unit protocol approves for blood [1].
Call the nephrologist when
- A test turns newly positive for HBsAg, anti-HBc, or HCV — same day. The unit reviews all patients’ results and serologic history; retesting is for the new case, not routine retesting of everyone [1].
- A previously immune patient’s anti-HBs falls below 10 mIU/mL.
- A patient has not responded to two full vaccine series.
- ALT rises without explanation.
- A patient dialyzed at another facility or while traveling.
- A needlestick or blood exposure occurs — follow your exposure protocol today.
Don’t
- Don’t give Heplisav-B to a patient on hemodialysis. CDC states its safety and effectiveness have not been established in adults on hemodialysis [2].
- Don’t end hepatitis B isolation because the viral load is undetectable or the patient is on an antiviral. Isolation continues while HBsAg is positive [1].
- Don’t return supplies or medications from the isolation station to general stock [1].
N11 — Infection Control: Hepatitis B and C, Vaccination, Isolation BACK
Back · why, and the evidence
Why
- Dialysis patients respond to standard hepatitis B vaccine far less often than the general population, and their antibody wanes faster; CDC calls for high-dose dialysis regimens, yearly anti-HBs, and a booster below 10 mIU/mL [1].
- Heplisav-B’s two-dose schedule is not a dialysis regimen; CDC lists Recombivax HB (3 doses) and Engerix-B (4 doses) for adults on hemodialysis [2].
- KDIGO 2022 recommends HCV screening every 6 months for in-center hemodialysis patients and monthly ALT [3].
- CDC 2023 recommends the triple panel (HBsAg, anti-HBs, total anti-HBc) to separate active infection, past infection, and immunity [4].
- CDC isolation for HBsAg-positive patients — separate room, dedicated machine and supplies, and staff not shared with susceptible patients — is the core of dialysis hepatitis B control [1].
Go deeper
- Mastery page: Infection Screening and Vaccination in Maintenance Hemodialysis
- Complete white paper: Screening and health maintenance in maintenance hemodialysis
- All dialysis nursing reference cards
References
- Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50(RR-5):1-43. PubMed 11349873
- Centers for Disease Control and Prevention. Hepatitis B vaccine administration (health care providers). Accessed 2026-09-26. cdc.gov
- KDIGO Hepatitis C Work Group. KDIGO 2022 guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD. Kidney Int. 2022;102(6S):S129-S205. PubMed 36410841
- Conners EE, et al. Screening and testing for hepatitis B virus infection: CDC recommendations — United States, 2023. MMWR Recomm Rep. 2023;72(1):1-25. PubMed 36893044
Reviewed by Andrew Bland, MD, FACP, FAAP · v1.0 draft 2026-09-26. For education; the physician’s written order and the unit protocol always govern.